#Netherlands #Julius Clinical #Peachtree BioResearch #CNS Research #Zeist

Julius Clinical and Peachtree BioResearch Solutions Unite

In a strategic move set to transform the clinical research landscape, Julius Clinical, a renowned Contract Research Organization (CRO) based in the Netherlands, and Peachtree BioResearch Solutions, a specialized CRO in the United States, have officially merged. This partnership creates a fully integrated global CRO that significantly strengthens capabilities in the field of central nervous system (CNS) research and other therapeutic areas.

A Natural Progression

Both companies have collaborated effectively for nearly a decade, paving the way for this significant merger. According to Martijn Wallert, CEO of Julius Clinical, the merger symbolizes a major advancement in their combined presence, particularly in North America and Europe. He emphasized the alignment of the companies' strengths, which enables them to become a more flexible and competent partner for clients seeking comprehensive clinical research services.

This merger is particularly noteworthy, given the increasing complexity and global demands of modern clinical research. The resulting organization aims to deliver end-to-end clinical research services, thereby improving global access for clients in Europe and North America. The combined expertise of the teams ensures that they can handle various clinical trials, including those addressing CNS, cardio-metabolic, renal, and rare diseases.

Enhancing Client Services

Kristy Nichols, CEO of Peachtree BioResearch Solutions, echoed Wallert’s sentiments, stating that this merger enhances their ability to serve clients by providing access to a robust international network and a more extensive range of services while retaining the personalized touch that defines their approach. Peachtree has earned its reputation as a dedicated service provider in the clinical development realm, especially for mid-sized biotech and pharmaceutical companies.

With the integration of their resources, clients will benefit from a highly coordinated service offering including Clinical Project Management, Clinical Monitoring, and Quality Assurance, among others. This capability expansion positions the merged organization to not only meet but exceed the evolving needs of the industry.

A Commitment to Science and Innovation

Founded in 2008, Julius Clinical has overseen over 380 clinical trials across 39 countries, leveraging its strong scientific leadership and operational excellence. This history of success will serve as a foundation for the newly merged company’s future endeavors. Both organizations are committed to ensuring that innovative therapies can reach patients worldwide, addressing the complexities that accompany modern drug development.

Empowered by the backing of Ampersand Capital Partners, an investment firm specializing in healthcare, the merger is poised to accelerate growth and further enhance Julius Clinical’s portfolio of services. The investment firm, with over $3 billion in assets under management, provides both financial support and strategic guidance to the newly formed CRO, facilitating a robust pathway toward operational expansion.

Conclusion

With this merger, Julius Clinical and Peachtree BioResearch Solutions are not just expanding their operational territories; they are setting a new standard in clinical research. Their unified efforts promise to streamline the clinical trial process and enhance patient outcomes while maintaining a focus on the critical areas of CNS, cardio-metabolic, renal, and rare diseases. As they embark on this journey, clients can expect a richer tapestry of services designed to innovate and inspire in the ever-evolving world of clinical research.